LIQUIDIA CORP (LQDA)
NASDAQ • Healthcare
$74.33
-$3.37 (-4.3%)
Market open
Last close at August 18, 2026 at 20:00 UTC
Fundamentals Charts
About LIQUIDIA CORP
Name
LIQUIDIA CORP
CEO
Roger A. Jeffs
Website
Industry
Healthcare
Year Founded
2004
Employees
216
Liquidia Corporation develops and commercializes pulmonary hypertension therapies in the healthcare sector, with a focus on pharmaceutical products for the United States market. Listed on the NASDAQ Capital Market as LQDA, Liquidia generated $158.3 million of revenue in FY2025 from a business centered on treprostinil-based treatments.
Fundamentals & Financials
Revenue (TTM)
$450.9M
Net Income (TTM)
$138.6M
EPS (TTM)
$1.57
ROA (TTM)
26.56%
Current Ratio
2.31
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Stay Ahead of the Market
Get premium market insights delivered directly to your inbox.
Quote Summary
Previous CloseDay Range$74.33$72.83 - $76.77
52 Week RangeAvg. Volume$21.15 - $93.611.7M
Market CapP/E Ratio$6.6B47.3
Peers & Related Assets
IBRXIMMUNITYBIO INC
$7.72-2.5%
COGTCOGENT BIOSCIENCES INC
$37.4-1.2%
DNLIDENALI THERAPEUTICS INC
$24.31-0.2%
RCUSARCUS BIOSCIENCES INC
$29.51-0.2%
GPCRStructure Therapeutics Inc.
OCULOCULAR THERAPEUTIX INC
ETNB89bio, Inc.
MESOMesoblast Limited
AGIOAGIOS PHARMACEUTICALS INC
GLPGGalapagos N.V.